JP2005531321A - マーカー遺伝子 - Google Patents
マーカー遺伝子 Download PDFInfo
- Publication number
- JP2005531321A JP2005531321A JP2004518691A JP2004518691A JP2005531321A JP 2005531321 A JP2005531321 A JP 2005531321A JP 2004518691 A JP2004518691 A JP 2004518691A JP 2004518691 A JP2004518691 A JP 2004518691A JP 2005531321 A JP2005531321 A JP 2005531321A
- Authority
- JP
- Japan
- Prior art keywords
- aldolase
- nephrotoxicity
- gene expression
- egf
- clusterin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 193
- 239000003550 marker Substances 0.000 title claims description 62
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims abstract description 191
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims abstract description 191
- 238000000034 method Methods 0.000 claims abstract description 146
- 231100000417 nephrotoxicity Toxicity 0.000 claims abstract description 146
- 206010029155 Nephropathy toxic Diseases 0.000 claims abstract description 144
- 230000007694 nephrotoxicity Effects 0.000 claims abstract description 144
- 102000003780 Clusterin Human genes 0.000 claims abstract description 119
- 108090000197 Clusterin Proteins 0.000 claims abstract description 119
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims abstract description 116
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 claims abstract description 116
- 108010028310 Calbindin 1 Proteins 0.000 claims abstract description 98
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 97
- 102000016838 Calbindin 1 Human genes 0.000 claims abstract description 96
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 96
- 210000003734 kidney Anatomy 0.000 claims abstract description 82
- 238000011282 treatment Methods 0.000 claims abstract description 56
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 54
- 102100036037 Podocin Human genes 0.000 claims abstract description 44
- 101710162479 Podocin Proteins 0.000 claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 230000031018 biological processes and functions Effects 0.000 claims abstract description 6
- 230000003907 kidney function Effects 0.000 claims abstract description 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract 35
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims abstract 35
- 101000868455 Rattus norvegicus Solute carrier organic anion transporter family member 1A3 Proteins 0.000 claims abstract 31
- 101000613820 Homo sapiens Osteopontin Proteins 0.000 claims abstract 28
- 102100040557 Osteopontin Human genes 0.000 claims abstract 28
- 230000014509 gene expression Effects 0.000 claims description 254
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 105
- 108010036949 Cyclosporine Proteins 0.000 claims description 103
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 96
- 229960001265 ciclosporin Drugs 0.000 claims description 94
- 102000004264 Osteopontin Human genes 0.000 claims description 93
- 108010081689 Osteopontin Proteins 0.000 claims description 93
- 239000003814 drug Substances 0.000 claims description 65
- 210000005084 renal tissue Anatomy 0.000 claims description 62
- 229940079593 drug Drugs 0.000 claims description 60
- 108020004999 messenger RNA Proteins 0.000 claims description 47
- 102000004169 proteins and genes Human genes 0.000 claims description 46
- 229940000406 drug candidate Drugs 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 27
- 208000024891 symptom Diseases 0.000 claims description 25
- 230000001988 toxicity Effects 0.000 claims description 25
- 231100000419 toxicity Toxicity 0.000 claims description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 21
- 229940127089 cytotoxic agent Drugs 0.000 claims description 19
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 19
- 239000002254 cytotoxic agent Substances 0.000 claims description 19
- 150000007523 nucleic acids Chemical group 0.000 claims description 18
- 238000012360 testing method Methods 0.000 claims description 17
- 101150009126 C4 gene Proteins 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 12
- 229930182912 cyclosporin Natural products 0.000 claims description 12
- 238000002493 microarray Methods 0.000 claims description 12
- 231100000252 nontoxic Toxicity 0.000 claims description 12
- 230000003000 nontoxic effect Effects 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 11
- 230000006698 induction Effects 0.000 claims description 11
- 230000003589 nefrotoxic effect Effects 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 9
- 229940126575 aminoglycoside Drugs 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 9
- 229960004316 cisplatin Drugs 0.000 claims description 9
- 210000003292 kidney cell Anatomy 0.000 claims description 9
- 231100000381 nephrotoxic Toxicity 0.000 claims description 9
- 229940124530 sulfonamide Drugs 0.000 claims description 9
- 150000003456 sulfonamides Chemical class 0.000 claims description 9
- 229960001967 tacrolimus Drugs 0.000 claims description 9
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 8
- 231100000433 cytotoxic Toxicity 0.000 claims description 8
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 claims description 8
- 229960004453 trimethadione Drugs 0.000 claims description 8
- 210000005239 tubule Anatomy 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 230000001629 suppression Effects 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 238000011529 RT qPCR Methods 0.000 claims description 6
- 230000001668 ameliorated effect Effects 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 238000004422 calculation algorithm Methods 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000003757 reverse transcription PCR Methods 0.000 claims description 6
- 231100000331 toxic Toxicity 0.000 claims description 6
- 230000002588 toxic effect Effects 0.000 claims description 6
- 108010028778 Complement C4 Proteins 0.000 claims description 5
- 231100000050 cytotoxic potential Toxicity 0.000 claims description 5
- 230000003013 cytotoxicity Effects 0.000 claims description 5
- 231100000135 cytotoxicity Toxicity 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 238000003018 immunoassay Methods 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 238000000636 Northern blotting Methods 0.000 claims description 4
- 108010018360 alpha 2u globulin Proteins 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 150000002891 organic anions Chemical class 0.000 claims description 4
- 230000004043 responsiveness Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 102000006382 Ribonucleases Human genes 0.000 claims description 3
- 108010083644 Ribonucleases Proteins 0.000 claims description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 238000002651 drug therapy Methods 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 101150084418 EGF gene Proteins 0.000 claims description 2
- 238000010195 expression analysis Methods 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 abstract description 14
- 230000001575 pathological effect Effects 0.000 abstract description 9
- 238000012544 monitoring process Methods 0.000 abstract description 8
- 238000013459 approach Methods 0.000 abstract description 2
- 239000013598 vector Substances 0.000 abstract description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 84
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 84
- 101800003838 Epidermal growth factor Proteins 0.000 description 81
- 102400001368 Epidermal growth factor Human genes 0.000 description 81
- 229940116977 epidermal growth factor Drugs 0.000 description 81
- 239000000523 sample Substances 0.000 description 63
- 241000700159 Rattus Species 0.000 description 49
- -1 OAT-K1 Proteins 0.000 description 42
- 230000000875 corresponding effect Effects 0.000 description 31
- 239000002773 nucleotide Substances 0.000 description 26
- 125000003729 nucleotide group Chemical group 0.000 description 26
- 230000000692 anti-sense effect Effects 0.000 description 22
- 230000008859 change Effects 0.000 description 18
- 230000001105 regulatory effect Effects 0.000 description 16
- 241000894007 species Species 0.000 description 16
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 206010061481 Renal injury Diseases 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 239000011575 calcium Substances 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229940063121 neoral Drugs 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108090000994 Catalytic RNA Proteins 0.000 description 5
- 102000053642 Catalytic RNA Human genes 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 231100000268 induced nephrotoxicity Toxicity 0.000 description 5
- 208000037806 kidney injury Diseases 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108091092562 ribozyme Proteins 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000013519 Lipocalin-2 Human genes 0.000 description 4
- 108010051335 Lipocalin-2 Proteins 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000007838 tissue remodeling Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 3
- 102000013382 Gelatinases Human genes 0.000 description 3
- 108010026132 Gelatinases Proteins 0.000 description 3
- 241001460678 Napo <wasp> Species 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 102000037054 SLC-Transporter Human genes 0.000 description 3
- 108091006207 SLC-Transporter Proteins 0.000 description 3
- 208000009911 Urinary Calculi Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 102000014823 calbindin Human genes 0.000 description 3
- 108060001061 calbindin Proteins 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002974 pharmacogenomic effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 244000105975 Antidesma platyphyllum Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010072104 Fructose intolerance Diseases 0.000 description 2
- 101000595193 Homo sapiens Podocin Proteins 0.000 description 2
- 101150017040 I gene Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000019298 Lipocalin Human genes 0.000 description 2
- 108050006654 Lipocalin Proteins 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000009424 haa Nutrition 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 210000000557 podocyte Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 208000008281 urolithiasis Diseases 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010004173 Basophilia Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019878 Hereditary fructose intolerance Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000755935 Mus musculus Fructose-bisphosphate aldolase B Proteins 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000007990 Organic Anion Transporters Human genes 0.000 description 1
- 108010089503 Organic Anion Transporters Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 101000898069 Rattus norvegicus Calbindin Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000994 contrast dye Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000005232 distal tubule cell Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229940025237 fructose 1,6-diphosphate Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 210000001282 glomerular podocyte Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013090 high-throughput technology Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000003064 k means clustering Methods 0.000 description 1
- 210000000738 kidney tubule Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100001210 nonnephrotoxic Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000005233 tubule cell Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0215509.1A GB0215509D0 (en) | 2002-07-04 | 2002-07-04 | Marker genes |
| PCT/EP2003/007111 WO2004005544A2 (en) | 2002-07-04 | 2003-07-03 | Marker genes for determining renal toxicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009233624A Division JP2010042019A (ja) | 2002-07-04 | 2009-10-07 | マーカー遺伝子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005531321A true JP2005531321A (ja) | 2005-10-20 |
| JP2005531321A5 JP2005531321A5 (enExample) | 2006-08-17 |
Family
ID=9939850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004518691A Pending JP2005531321A (ja) | 2002-07-04 | 2003-07-03 | マーカー遺伝子 |
| JP2009233624A Pending JP2010042019A (ja) | 2002-07-04 | 2009-10-07 | マーカー遺伝子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009233624A Pending JP2010042019A (ja) | 2002-07-04 | 2009-10-07 | マーカー遺伝子 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060008804A1 (enExample) |
| EP (2) | EP1925677A3 (enExample) |
| JP (2) | JP2005531321A (enExample) |
| CN (1) | CN1688715A (enExample) |
| AU (1) | AU2003250879B2 (enExample) |
| BR (1) | BR0312405A (enExample) |
| CA (1) | CA2493860A1 (enExample) |
| GB (1) | GB0215509D0 (enExample) |
| IL (1) | IL165883A0 (enExample) |
| WO (1) | WO2004005544A2 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012508382A (ja) * | 2008-11-10 | 2012-04-05 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| JP2012510058A (ja) * | 2008-11-22 | 2012-04-26 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| JP2012524883A (ja) * | 2008-08-14 | 2012-10-18 | ホスピタル クリニク アイ プロビンシアル デ バルセロナ | 腎臓障害生物マーカとしてのｗｎｔ１ |
| JP2013031375A (ja) * | 2011-07-29 | 2013-02-14 | Medichrome:Kk | 遺伝子発現変動解析による化学物質の毒性評価方法 |
| JP2016504017A (ja) * | 2012-10-24 | 2016-02-12 | リージェンメドティーエックス， エルエルシー | 腎細胞集団及びその使用 |
| JP2016515514A (ja) * | 2013-03-15 | 2016-05-30 | ライフライン サイエンティフィック インコーポレイテッドＬｉｆｅｌｉｎｅ Ｓｃｉｅｎｔｉｆｉｃ， Ｉｎｃ． | 臓器または組織の生存性を判定するためのグルコースセンサを備えた搬送装置 |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004500879A (ja) | 2000-06-16 | 2004-01-15 | バイオジェン インコーポレイテッド | 腎の調節エレメントおよびそれらの使用方法 |
| DK1401869T3 (da) | 2001-06-01 | 2008-04-28 | Biogen Idec Inc | Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 |
| CA2512138C (en) | 2002-12-30 | 2013-07-16 | Biogen Idec Ma Inc. | Kim-1 antagonists and use to modulate immune system |
| US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
| CA2565701A1 (en) * | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| DK1831699T3 (da) * | 2004-12-20 | 2010-03-15 | Antibodyshop As | Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme |
| EP1865985B1 (en) | 2005-03-02 | 2010-08-25 | Biogen Idec MA Inc. | Kim-1 antibodies for treatment of th2-mediated conditions |
| US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
| US20070087387A1 (en) | 2005-04-21 | 2007-04-19 | Prasad Devarajan | Method for the Early Detection of Renal Disease Using Proteomics |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| US20080090304A1 (en) * | 2006-10-13 | 2008-04-17 | Barasch Jonathan Matthew | Diagnosis and monitoring of chronic renal disease using ngal |
| PL2035835T3 (pl) * | 2006-05-30 | 2012-05-31 | Antibodyshop As | Sposoby szybkiej oceny ciężkości urazu |
| WO2008017306A1 (en) * | 2006-08-07 | 2008-02-14 | Antibodyshop A/S | Diagnostic test to exclude significant renal injury |
| EP2137538B1 (en) * | 2007-03-21 | 2014-04-09 | Bioporto Diagnostics A/s | Diagnostic test for renal injury |
| EP2479571A3 (en) | 2007-03-26 | 2012-09-26 | Novartis AG | Predictive renal safety biomarkers and biomarker signatures to monitor kidney function |
| US20090104649A1 (en) | 2007-06-11 | 2009-04-23 | Garovic Vesna D | Markers for preeclampsia |
| US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
| EP2215481B2 (en) * | 2007-11-15 | 2017-01-18 | Bioporto Diagnostics A/S | Diagnostic use of individual molecular forms of a biomarker |
| EP2075343A1 (en) * | 2007-12-21 | 2009-07-01 | Gert Mayer | A method of diagnosing a progressive disease |
| US8338096B2 (en) * | 2008-04-15 | 2012-12-25 | Rainer Oberbauer | Markers of acute kidney failure |
| US7977110B2 (en) | 2008-06-02 | 2011-07-12 | Children's Hospital Medical Center | Method for distinguishing between kidney dysfunctions |
| WO2010054025A1 (en) * | 2008-11-05 | 2010-05-14 | Abbott Laboratories | Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use |
| EP2379752B1 (fr) * | 2009-01-19 | 2015-09-30 | Biomérieux S.A. | Procedes pour determiner la susceptibilite a contracter une infection nosocomiale chez un patient et pour etablir un pronostic d'evolution d'un syndrome septique |
| DK2391653T3 (en) * | 2009-01-28 | 2015-02-09 | Ind Tech Res Inst | Biomarkers associated nephropathy |
| WO2011017685A1 (en) * | 2009-08-07 | 2011-02-10 | Rules-Based Medicine, Inc. | Methods and devices for detecting kidney transplant rejection |
| ES2530866T3 (es) | 2009-12-21 | 2015-03-06 | Mayo Foundation | Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF |
| US9476868B2 (en) | 2009-12-23 | 2016-10-25 | Hill's Pet Nutrition, Inc. | Compositions and methods for diagnosing and treating kidney disorders in a canine |
| JP2013529907A (ja) | 2010-05-24 | 2013-07-25 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | Ｎｇａｌタンパク質変異体及びその使用 |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2845117A1 (en) * | 2011-09-14 | 2013-03-21 | Basf Se | Means and methods for assessing kidney toxicity |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP2925337B1 (en) | 2012-11-21 | 2019-07-03 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
| WO2014182330A1 (en) | 2013-05-06 | 2014-11-13 | Hitachi Chemical Company Ltd | Devices and methods for capturing target molecules |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| WO2015153860A1 (en) * | 2014-04-04 | 2015-10-08 | Somalogic, Inc. | Glomerular filtration rate biomarkers and uses thereof |
| WO2015160805A1 (en) * | 2014-04-15 | 2015-10-22 | The Brigham And Women's Hospital, Inc. | Circulating kim-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney |
| US10712349B2 (en) | 2014-04-15 | 2020-07-14 | The Brigham And Women's Hospital, Inc. | Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney |
| US10801066B2 (en) | 2014-09-05 | 2020-10-13 | American University Of Beirut | Determination of risk for development of cardiovascular disease by measuring urinary levels of podocin and nephrin messenger RNA |
| WO2016077537A1 (en) * | 2014-11-12 | 2016-05-19 | Hitachi Chemical Co., Ltd. | Method and device for diagnosing organ injury |
| WO2016208776A1 (ja) | 2015-06-25 | 2016-12-29 | 株式会社国際電気通信基礎技術研究所 | 多器官連関システムを基盤とした予測装置、及び予測プログラム |
| JP6624704B2 (ja) | 2015-08-31 | 2019-12-25 | 日立化成株式会社 | 尿路上皮疾患の評価のための分子法 |
| CN114594268A (zh) | 2016-03-29 | 2022-06-07 | 无限生物制药公司 | 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法 |
| JP6332780B2 (ja) | 2016-03-29 | 2018-05-30 | 株式会社国際電気通信基礎技術研究所 | 医薬組成物又は食品組成物、及び有効成分の体内での効果の評価方法 |
| EP3472347B1 (en) * | 2016-06-17 | 2023-01-04 | F. Hoffmann-La Roche AG | In vitro nephrotoxicity screening assay |
| US12174201B2 (en) | 2017-10-12 | 2024-12-24 | Cedars-Sinai Medical Center | Prognosis and progression biomarkers for chronic kidney disease |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000012760A2 (en) * | 1998-08-28 | 2000-03-09 | Incyte Pharmaceuticals, Inc. | Toxicological response markers |
| WO2001094636A2 (en) * | 2000-06-05 | 2001-12-13 | Genetics Inst | Compositions, kits, and methods for identification and modulation of type i diabetes |
| WO2001098539A2 (en) * | 2000-06-21 | 2001-12-27 | Hitachi Chemical Co., Ltd. | Gene markers for lung cancer |
| WO2002010453A2 (en) * | 2000-07-31 | 2002-02-07 | Gene Logic, Inc. | Molecular toxicology modeling |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA951461B (en) * | 1994-02-22 | 1996-01-24 | Univ Illinois | Genes and genetic elements associated with sensitivity to platimun-based drugs |
| US6586389B1 (en) * | 1998-01-22 | 2003-07-01 | Administrators Of The Tulane Educational Fund | Cubilin protein, DNA sequences encoding cubilin and uses thereof |
| WO2000047761A2 (en) * | 1999-02-12 | 2000-08-17 | Phase-1 Molecular Toxicology, Inc. | High-throughput toxicological testing using cultured organisms and cells |
| US20010034023A1 (en) * | 1999-04-26 | 2001-10-25 | Stanton Vincent P. | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing |
| AU1466001A (en) * | 1999-11-05 | 2001-05-14 | Phase-1 Molecular Toxicology | Methods of determining individual hypersensitivity to an agent |
| US20020037508A1 (en) * | 2000-01-19 | 2002-03-28 | Michele Cargill | Human single nucleotide polymorphisms |
| JP2004500879A (ja) * | 2000-06-16 | 2004-01-15 | バイオジェン インコーポレイテッド | 腎の調節エレメントおよびそれらの使用方法 |
| AU2001271998A1 (en) * | 2000-07-13 | 2002-01-30 | The Johns Hopkins University School Of Medicine | Detection and treatment of polycystic kidney disease |
| AU2001281322A1 (en) * | 2000-07-13 | 2002-01-30 | Biogen, Inc. | Methods of identifying renal protective factors |
| DE10056802B4 (de) * | 2000-11-14 | 2005-06-16 | Epigenomics Ag | Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik |
| CA2440008A1 (en) * | 2001-01-29 | 2002-08-29 | Phase-1 Molecular Toxicology, Inc. | Rat toxicologically relevant genes and uses thereof |
-
2002
- 2002-07-04 GB GBGB0215509.1A patent/GB0215509D0/en not_active Ceased
-
2003
- 2003-07-03 CN CNA038187833A patent/CN1688715A/zh active Pending
- 2003-07-03 JP JP2004518691A patent/JP2005531321A/ja active Pending
- 2003-07-03 EP EP07119607A patent/EP1925677A3/en not_active Withdrawn
- 2003-07-03 US US10/518,575 patent/US20060008804A1/en not_active Abandoned
- 2003-07-03 WO PCT/EP2003/007111 patent/WO2004005544A2/en not_active Ceased
- 2003-07-03 CA CA002493860A patent/CA2493860A1/en not_active Abandoned
- 2003-07-03 AU AU2003250879A patent/AU2003250879B2/en not_active Ceased
- 2003-07-03 EP EP03762612A patent/EP1521847A2/en not_active Withdrawn
- 2003-07-03 BR BR0312405-3A patent/BR0312405A/pt not_active IP Right Cessation
-
2004
- 2004-12-20 IL IL16588304A patent/IL165883A0/xx unknown
-
2009
- 2009-10-07 JP JP2009233624A patent/JP2010042019A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000012760A2 (en) * | 1998-08-28 | 2000-03-09 | Incyte Pharmaceuticals, Inc. | Toxicological response markers |
| WO2001094636A2 (en) * | 2000-06-05 | 2001-12-13 | Genetics Inst | Compositions, kits, and methods for identification and modulation of type i diabetes |
| WO2001098539A2 (en) * | 2000-06-21 | 2001-12-27 | Hitachi Chemical Co., Ltd. | Gene markers for lung cancer |
| WO2002010453A2 (en) * | 2000-07-31 | 2002-02-07 | Gene Logic, Inc. | Molecular toxicology modeling |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012524883A (ja) * | 2008-08-14 | 2012-10-18 | ホスピタル クリニク アイ プロビンシアル デ バルセロナ | 腎臓障害生物マーカとしてのｗｎｔ１ |
| JP2012508382A (ja) * | 2008-11-10 | 2012-04-05 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| JP2012510058A (ja) * | 2008-11-22 | 2012-04-26 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| JP2015064381A (ja) * | 2008-11-22 | 2015-04-09 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| JP2013031375A (ja) * | 2011-07-29 | 2013-02-14 | Medichrome:Kk | 遺伝子発現変動解析による化学物質の毒性評価方法 |
| JP2016504017A (ja) * | 2012-10-24 | 2016-02-12 | リージェンメドティーエックス， エルエルシー | 腎細胞集団及びその使用 |
| JP2019141067A (ja) * | 2012-10-24 | 2019-08-29 | インリージェン | 腎細胞集団及びその使用 |
| US11369639B2 (en) | 2012-10-24 | 2022-06-28 | Prokidney | Renal cell populations and uses thereof |
| US12409191B2 (en) | 2012-10-24 | 2025-09-09 | Prokidney | Renal cell populations and uses thereof |
| JP2016515514A (ja) * | 2013-03-15 | 2016-05-30 | ライフライン サイエンティフィック インコーポレイテッドＬｉｆｅｌｉｎｅ Ｓｃｉｅｎｔｉｆｉｃ， Ｉｎｃ． | 臓器または組織の生存性を判定するためのグルコースセンサを備えた搬送装置 |
| US10420337B2 (en) | 2013-03-15 | 2019-09-24 | Lifeline Scientific, Inc. | Transporter with a glucose sensor for determining viability of an organ or tissue |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004005544A3 (en) | 2004-04-22 |
| AU2003250879B2 (en) | 2007-07-26 |
| CN1688715A (zh) | 2005-10-26 |
| EP1925677A2 (en) | 2008-05-28 |
| IL165883A0 (en) | 2006-01-15 |
| CA2493860A1 (en) | 2004-01-15 |
| EP1521847A2 (en) | 2005-04-13 |
| WO2004005544A2 (en) | 2004-01-15 |
| AU2003250879A1 (en) | 2004-01-23 |
| US20060008804A1 (en) | 2006-01-12 |
| EP1925677A3 (en) | 2008-07-02 |
| BR0312405A (pt) | 2005-04-26 |
| GB0215509D0 (en) | 2002-08-14 |
| JP2010042019A (ja) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010042019A (ja) | マーカー遺伝子 | |
| EP1064404B1 (en) | P53-regulated genes | |
| CN101679525B (zh) | 用于监测肾功能的预测性的肾安全性生物标志物和生物标志物标签 | |
| US8329410B2 (en) | Method for diagnosing kidney disease comprising detecting the level of annexin A2 | |
| Hakkola et al. | Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers | |
| JP2005531321A5 (enExample) | ||
| Yang et al. | The secreted micropeptide C4orf48 enhances renal fibrosis via an RNA-binding mechanism | |
| Radrizzani et al. | Differential expression of CPD1 during postnatal development in the mouse cerebellum | |
| Cheval et al. | Plasticity of mouse renal collecting duct in response to potassium depletion | |
| US20200241005A1 (en) | Compositions and methods for the diagnosis and treatment of diseases of the liver | |
| JP2004187620A (ja) | 腎疾患の疾患マーカーおよびその利用 | |
| US7060457B2 (en) | Aberrant glutamate transporters and methods of use | |
| CA2440008A1 (en) | Rat toxicologically relevant genes and uses thereof | |
| US7579152B2 (en) | SENP1 as a marker of cancer development and target for cancer therapy | |
| JP2004505637A (ja) | ガン関連ｓｉｍ２遺伝子 | |
| JP2005529603A (ja) | 糖尿病を予防、治療、および診断するための組成物および方法 | |
| US20050079496A1 (en) | Methods for diagnosing and treating neoplasias using nf-at transcriptions factors | |
| KR102242286B1 (ko) | 중간엽줄기세포의 신장섬유화 치료효과 예측용 바이오마커 조성물 | |
| KR102337954B1 (ko) | 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법 | |
| EP1619504A1 (en) | Novel use of the kinases RSK4 and PAK5 | |
| JP2006518998A (ja) | Ｐａｃ−１（ｄｕｓｐ２）を使用する炎症性疾患の診断方法及び治療方法 | |
| HK1084699A (en) | Marker genes for determining renal toxicity | |
| KR20090034932A (ko) | 파킨슨씨 질환 치료 및 진단을 위한 ｇｐｒｃ 변형체의 동정 및 용도 | |
| AU2002333399A1 (en) | Methods for diagnosing and treating neoplasias using NF-AT transcription factors | |
| WO2001088193A2 (en) | Follicle stimulating hormone stimulated genes and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060628 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060628 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090707 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091007 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091110 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100209 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100217 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100310 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100317 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100506 |